The move came after the NIH director refused Trump’s request to cut Harvard grants in an Oval Office meeting.

YouTube video by Stanford Department of Medicine

Durcabtagene autoleucel, a rapidly manufactured BCMA-directed CAR T cell therapy, was safe and efficacious in relapsed/refractory multiple myeloma.

Durcabtagene autoleucel, a rapidly manufactured BCMA-directed CAR T cell therapy, was safe and efficacious in relapsed/refractory multiple myeloma.

Postdoctoral Associate Trowbridge Lab Bar Harbor, ME A Postdoctoral Associate position is available in Dr. Jennifer Trowbridge’s laboratory at The Jackson Laboratory in Bar Harbor, Maine. The Trowbrid...

PURPOSEThe diagnosis of smoldering multiple myeloma (SMM) primarily relies on clinical features such as plasma cell involvement, immunoglobulin protein levels, and end-organ damage. However, as early ...

Cancer relapse after treatment invariably proceeds from the persistence and progression of measurable residual disease (MRD), an ultrasmall malignant population. Despite the poor prognostic impact est...

The authors present a molecular classification of acute leukemia using 5-methylcytosine signatures, together with a neural network-based classifier for clinical use.

Alice T. Shaw, MD, PhD, was named Chair of the Department of Medical Oncology at Dana-Farber Cancer Institute, in an announcement today.